Friday, September 25, 2020

Oppenheimer lifts NovoCure Limited [NVCR] price estimate. Who else is bullish?

Must read

Seaport Global Securities lifts Mondelez International Inc. [MDLZ] price estimate. Who else is bullish?

Mondelez International Inc. plunged by -$0.67 during the normal trading session on Monday and reaching a high of $56.15 during the day while...

For The Wendy’s Company [WEN], Evercore ISI sees a rise to $25. What next?

The Wendy's Company jumped around 0.41 points on Tuesday, while shares priced at $21.07 at the close of the session, up 1.98%. The...

NanoVibronix Inc. [NAOV] Stock trading around $1.20 per share: What’s Next?

NanoVibronix Inc. stock went on an upward path that rose over 103.46% on Tuesday, amounting to a one-week price increase of more than...

MBIA Inc. [MBI] Revenue clocked in at $339.00 million, down -34.95% YTD: What’s Next?

MBIA Inc. surged by $0.19 during the normal trading session on Tuesday and reaching a high of $6.19 during the day while it...

NovoCure Limited [NASDAQ: NVCR] stock went on an upward path that rose over 2.61% on Tuesday, amounting to a one-week price decrease of less than -0.80%.

Over the last 12 months, NVCR stock rose by 4.43%. The one-year NovoCure Limited stock forecast points to a potential downside of -3.17. The average equity rating for NVCR stock is currently 2.60, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $8.52 billion, with 100.72 million shares outstanding and 84.42 million shares in the current float. Compared to the average trading volume of 914.58K shares, NVCR stock reached a trading volume of 1307708 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on NovoCure Limited [NVCR]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVCR shares is $79.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVCR stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Oppenheimer have made an estimate for NovoCure Limited shares, keeping their opinion on the stock as Perform, with their previous recommendation back on June 01, 2020. The new note on the price target was released on May 01, 2020, representing the official price target for NovoCure Limited stock. Previously, the target price had yet another raise to $58, while Evercore ISI analysts kept a Underperform rating on NVCR stock. On March 05, 2020, analysts increased their price target for NVCR shares from 85 to 90.

The Average True Range (ATR) for NovoCure Limited is set at 2.56, with the Price to Sales ratio for NVCR stock in the period of the last 12 months amounting to 20.82. The Price to Book ratio for the last quarter was 30.86, with the Price to Cash per share for the same quarter was set at 3.34. Price to Free Cash Flow for NVCR in the course of the last twelve months was 397.98 with Quick ratio for the last quarter at 5.40.

NVCR Stock Performance Analysis:

NovoCure Limited [NVCR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.80. With this latest performance, NVCR shares gained by 3.86% in over the last four-week period, additionally plugging by 11.92% over the last 6 months – not to mention a rise of 4.43% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVCR stock in for the last two-week period is set at 63.40, with the RSI for the last a single of trading hit 59.01, and the three-weeks RSI is set at 62.53 for NovoCure Limited [NVCR]. The present Moving Average for the last 50 days of trading for this stock 71.78, while it was recorded at 82.73 for the last single week of trading, and 74.22 for the last 200 days.

Insight into NovoCure Limited Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and NovoCure Limited [NVCR] shares currently have an operating margin of -0.17 and a Gross Margin at +74.87. NovoCure Limited’s Net Margin is presently recorded at -2.06.

Return on Total Capital for NVCR is now -0.18, given the latest momentum, and Return on Invested Capital for the company is -2.25. Return on Equity for this stock declined to -4.38, with Return on Assets sitting at -1.77. When it comes to the capital structure of this company, NovoCure Limited [NVCR] has a Total Debt to Total Equity ratio set at 77.23. Additionally, NVCR Total Debt to Total Capital is recorded at 43.58, with Total Debt to Total Assets ending up at 35.08. Long-Term Debt to Equity for the company is recorded at 75.10, with the Long-Term Debt to Total Capital now at 42.38.

Reflecting on the efficiency of the workforce at the company, NovoCure Limited [NVCR] managed to generate an average of -$9,246 per employee. Receivables Turnover for the company is 6.32 with a Total Asset Turnover recorded at a value of 0.86.NovoCure Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.40 and a Current Ratio set at 5.70.

NVCR Stock EPS

With the latest financial reports released by the company, NovoCure Limited posted 0.02/share EPS, while the average EPS was predicted by analysts to be reported at -0.05/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 140.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVCR.

NovoCure Limited [NVCR] Insider Position Details

There are presently around $5,675 million, or 69.20% of NVCR stock, in the hands of institutional investors. The top three institutional holders of NVCR stocks are: FMR LLC with ownership of 10,438,534, which is approximately -11.83% of the company’s market cap and around 1.50% of the total institutional ownership; BAILLIE GIFFORD & CO, holding 7,903,720 shares of the stock with an approximate value of $648.82 million in NVCR stocks shares; and VANGUARD GROUP INC, currently with $613.59 million in NVCR stock with ownership of nearly 0.76% of the company’s market capitalization.

Positions in NovoCure Limited stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 139 institutional holders increased their position in NovoCure Limited [NASDAQ:NVCR] by around 8,848,458 shares. Additionally, 137 investors decreased positions by around 10,172,841 shares, while 41 investors held positions by with 50,108,522 shares. The mentioned changes placed institutional holdings at 69,129,821 shares, according to the latest SEC report filing. NVCR stock had 46 new institutional investments in for a total of 1,402,904 shares, while 55 institutional investors sold positions of 1,659,413 shares during the same period.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Market cap of Smith & Wesson Brands Inc. [SWBI] reaches 917.54M – now what?

Smith & Wesson Brands Inc. gained 2.90% on the last trading session, reaching $15.96 price per share at the time. Smith & Wesson...

Wells Fargo Downgrade TETRA Technologies Inc. [TTI]. What else is Wall St. saying?

TETRA Technologies Inc. surged by $0.0 during the normal trading session on Thursday and reaching a high of $0.53 during the day while...

Craig Hallum slashes price target on FuelCell Energy Inc. [FCEL] – find out why.

FuelCell Energy Inc. traded at a high on 09/24/20, posting a 2.24 gain after which it closed the day’ session at $2.28. The...

H.C. Wainwright lifts Clovis Oncology Inc. [CLVS] price estimate. Who else is bullish?

Clovis Oncology Inc. price plunged by -4.61 percent to reach at -$0.27. A sum of 4551611 shares traded at recent session while its...

LogicBio Therapeutics Inc. [LOGC] stock Initiated by ROTH Capital analyst, price target now $26

LogicBio Therapeutics Inc. gained 29.51% or 1.59 points to close at $7.00 with a heavy trading volume of 1179926 shares. It opened the...